{{GNF_Protein_box
 | Name = 促血小板生成素
 | image = Protein_THPO_PDB_1v7m.png
 | image_source = [[蛋白質資料庫|蛋白質資料庫]]（PDB）以1v7m爲基礎渲染的圖片
 | PDB = {{PDB2|1V7M}}, {{PDB2|1V7N}}
 | HGNCid = 11795
 | MGIid = 101875
 | Symbol = THPO
 | AltSymbols =; MGDF; MKCSF; ML; MPLLG; THCYT1; TPO
 | IUPHAR = 
 | ChEMBL = 1293256
 | OMIM = 600044
 | ECnumber = 
 | Homologene = 398
 | GeneAtlas_image1 = PBB_GE_THPO_211155_s_at_tn.png
 | GeneAtlas_image2 = PBB_GE_THPO_211154_at_tn.png
 | GeneAtlas_image3 = PBB_GE_THPO_211831_s_at_tn.png
 | Protein_domain_image = 
 | Function = {{GNF_GO|id=GO:0005125 |text = cytokine activity}} {{GNF_GO|id=GO:0005179 |text = hormone activity}} {{GNF_GO|id=GO:0008083 |text = growth factor activity}}
 | Component = {{GNF_GO|id=GO:0005615 |text = extracellular space}}
 | Process = {{GNF_GO|id=GO:0001934 |text = positive regulation of protein phosphorylation}}{{GNF_GO|id=GO:0007275 |text = multicellular organismal development}} {{GNF_GO|id=GO:0007596 |text = blood coagulation}} {{GNF_GO|id=GO:0008283 |text = cell proliferation}} {{GNF_GO|id=GO:0030099 |text = myeloid cell differentiation}} {{GNF_GO|id=GO:0030168 |text = platelet activation}}{{GNF_GO|id=GO:0038163 |text = thrombopoietin-mediated signaling pathway}} {{GNF_GO|id=GO:0045654|text = positive regulation of megakaryocyte differentiation}} {{GNF_GO|id=GO:0051897 |text = positive regulation of protein kinase B signaling}} {{GNF_GO|id=GO:0070374 |text = positive regulation of ERK1 and ERK2 cascade}}
 | Hs_EntrezGene = 7066
 | Hs_Ensembl = ENSG00000090534
 | Hs_RefseqmRNA = NM_000460
 | Hs_RefseqProtein = NP_000451
 | Hs_GenLoc_db = hg19
 | Hs_GenLoc_chr = 3
 | Hs_GenLoc_start = 184089723
 | Hs_GenLoc_end = 184095932
 | Hs_Uniprot = P40225
 | Mm_EntrezGene = 21832
 | Mm_Ensembl = ENSMUSG00000022847
 | Mm_RefseqmRNA = NM_001173505
 | Mm_RefseqProtein = NP_001166976
 | Mm_GenLoc_db = mm10
 | Mm_GenLoc_chr = 16
 | Mm_GenLoc_start = 20725158
 | Mm_GenLoc_end = 20734511
 | Mm_Uniprot = P40226
}}

'''促血小板生成素'''（{{lang-en|Thrombopoietin}}，縮寫爲「{{lang|en|THPO}}」），亦作「'''巨核細胞生長衍生因子'''」（{{lang|en|MGDF}}），是一種人體內由促血小板生成素（{{lang|en|THPO}}）[[基因|基因]]編碼的類[[激素|激素]]。其化學本質爲[[糖蛋白|糖蛋白]]，主要由腎臟和肝臟分泌，能刺激可以產生大量血小板的[[巨核細胞|巨核細胞]]的形成和分化，進而促進血小板的生成<ref name=Kaushansky2006>{{cite journal |author=Kaushansky K |title=Lineage-specific hematopoietic growth factors |journal=N. Engl. J. Med. |volume=354 |issue=19 |pages=2034–45 |year=2006 |pmid=16687716 |doi=10.1056/NEJMra052706}}</ref>。這種蛋白質是{{lang|en|MLP/C_MPL}}的[[配體_(生物化學)|配體]]。{{lang|en|MLP/C_MPL}}是一種骨髓增生性白血病病毒癌基因的表達產物<ref name="entrez">{{cite web | title = Entrez Gene: THPO thrombopoietin (myeloproliferative leukemia virus oncogene ligand, megakaryocyte growth and development factor)| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=7066| accessdate =2015-06-15 }}</ref>。

== 編碼基因 ==
編碼促血小板生成素的基因位於人[[3號染色體|3號染色體]]的長臂上（q26.3-27）。某些[[白血病|白血病]]患者和某些遺傳性{{link-en|血小板增多症|Thrombocytosis}}患者的該區段基因處存在異常。该基因的前155個[[鹼基對|鹼基對]]與[[紅血球生成素|紅血球生成素]]同源<ref>{{OMIM|600044}}</ref>。

== 功能和調節方式 ==
肝臟中的實質細胞和[[肝竇|肝竇]]內皮細胞、腎臟中的近曲小管細胞能合成促血小板生成素。另外，橫紋肌細胞和骨髓基質細胞也能合成少量的促血小板生成素<ref name=Kaushansky2006/>。在肝臟中，{{link-en|白細胞介素6|Interleukin 6}}（IL-6）能夠促進促血小板生成素的分泌<ref name=Kaushansky2006/>。

促血小板生成素能夠促進巨核細胞的成熟和血小板的形成，不過通過去除促血小板生成素受體的研究卻表明這種激素亦有促進造血的功能<ref name=Kaushansky2006/>。

促血小板生成素分泌過程中存在的[[负反馈#生物|負反饋調節]]與內分泌學中大部分的反饋調節機制都不一樣：負反饋效應是直接作用於激素本身的——MPL受體（CD 110）能將促血小板生成素綁定到血小板上等待分解，從而抑制其與巨核細胞的結合<ref name=Kaushansky2006/>。上述的調節機制使得人體內的促血小板生成素含量能夠達到相對穩定的狀態。

==臨床應用==
儘管科學家進行了大量的實驗，但促血小板生成素到目前爲止在臨床上還沒有發現療效。理論上講，促血小板可能可以應用於血小板的捐獻<ref>{{cite journal |author=Kuter DJ, Goodnough LT, Romo J, ''et al.'' |title=Thrombopoietin therapy increases platelet yields in healthy platelet donors |journal=Blood |volume=98 |issue=5 |pages=1339–45 |year=2001 |pmid=11520780 |url=http://www.bloodjournal.org/cgi/content/full/98/5/1339 |doi=10.1182/blood.V98.5.1339 |access-date=2015-05-31 |archive-url=https://web.archive.org/web/20081203153507/http://www.bloodjournal.org/cgi/content/full/98/5/1339 |archive-date=2008-12-03 |dead-url=yes }}</ref>、骨髓抑制性化療後血小板數目的恢復等方面<ref name=Kaushansky2006/>。

有關修改重組促血小板生成素的實驗使健康的志願者體內產生針對內源型血小板生成素的抗体，进而患上血小板減少症，之後實驗就停止了<ref name="pmid11719360">{{cite journal | author = Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ | title = Thrombocytopenia caused by the development of antibodies to thrombopoietin | journal = Blood | volume = 98 | issue = 12 | pages = 3241–8 |date=December 2001 | pmid = 11719360 | doi = 10.1182/blood.V98.12.3241 }}</ref>。隨後，科學家轉爲採用{{link-en|羅米斯亭|Romiplostim}}和{{link-en|艾曲波帕|Eltrombopag}}這兩種與促血小板生成素結構不同，但作用機理相同的藥物<ref name="pmid21864167">{{cite journal | author = Imbach P, Crowther M | title = Thrombopoietin-receptor agonists for primary immune thrombocytopenia | journal = N. Engl. J. Med. | volume = 365 | issue = 8 | pages = 734–41 |date=August 2011 | pmid = 21864167 | doi = 10.1056/NEJMct1014202 }}</ref>。

目前，科學家正在研究一種四價肽類的化合物和一些小分子的藥劑<ref name=Kaushansky2006/>，以及一些''c-Mpl''的非肽類配體類藥劑，來充當促血小板生成素的代用品<ref>{{cite journal |author=Nakamura T, Miyakawa Y, Miyamura A, ''et al.'' |title=A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis |journal=Blood |volume=107 |issue=11 |pages=4300–7 |year=2006 |pmid=16484588 |doi=10.1182/blood-2005-11-4433}}</ref><ref>{{cite journal |author=Jenkins JM, Williams D, Deng Y, ''et al.'' |title=Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist |journal=Blood |volume=109 |issue=11 |pages=4739–41 |year=2007 |pmid=17327409 |doi=10.1182/blood-2006-11-057968}}</ref>。

== 發現 ==
1994年，5個獨立的研究小組成功克隆出了促血小板生成素。在促血小板生成素被研究清楚之前長達30年的時間裏，它的功能都被認爲是與[[細胞表面受體|細胞表面受體]]''c-Mpl''相連，在舊的出版物中，促血小板生成素甚至被稱爲「c-Mpl 配體」（''c-Mpl ligand''）。促血小板生成素是I類造血細胞因子之一<ref name=Kaushansky2006/>。

==參見==
*[[血小板|血小板]]
*[[紅血球生成素|紅血球生成素]]

==參考==
{{reflist}}

== 擴展閱讀 ==
{{refbegin | 2}}
* {{cite journal | author = Hitchcock IS, Kaushansky K | title = Thrombopoietin from beginning to end | journal = Br. J. Haematol. | volume = 165 | issue = 2 | pages = 259–68 | year = 2014 | pmid = 24499199 | doi = 10.1111/bjh.12772 }}
* {{cite journal | author = Wörmann B | title = Clinical indications for thrombopoietin and thrombopoietin-receptor agonists | journal = Transfus Med Hemother | volume = 40 | issue = 5 | pages = 319–25 | year = 2013 | pmid = 24273485 | pmc = 3822275 | doi = 10.1159/000355006 }}
* {{cite journal | author = Kuter DJ | title = The biology of thrombopoietin and thrombopoietin receptor agonists | journal = Int. J. Hematol. | volume = 98 | issue = 1 | pages = 10–23 | year = 2013 | pmid = 23821332 | doi = 10.1007/s12185-013-1382-0 }}
* {{cite journal | author = Lupia E, Goffi A, Bosco O, Montrucchio G | title = Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases | journal = Mediators Inflamm. | volume = 2012 | issue = | pages = 390892 | year = 2012 | pmid = 22577249 | pmc = 3337636 | doi = 10.1155/2012/390892 }}
* {{cite journal | author = Liebman HA, Pullarkat V | title = Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics | journal = Hematology Am Soc Hematol Educ Program | volume = 2011 | issue = | pages = 384–90 | year = 2011 | pmid = 22160062 | doi = 10.1182/asheducation-2011.1.384 }}
{{refend}}

==外部連結==
* [http://www.priory.com/med/thrombo.htm Longer summary on thrombopoietin]{{Wayback|url=http://www.priory.com/med/thrombo.htm |date=20150919043914 }}

{{PDB Gallery|geneid=7066}}
{{Cytokine receptor modulators|state=autocollapse}}
{{Glycoproteins}}

[[Category:生长因子|Category:生长因子]]
[[Category:糖蛋白|Category:糖蛋白]]
[[Category:激素|Category:激素]]